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Abstract: Escherichia coli O157:H7 is the predominant cause of diarrhea-associated hemolytic uremic
syndrome (HUS) worldwide. Its cardinal virulence traits are Shiga toxins, which are encoded by
stx genes, the most common of which are stx1a, stx2a, and stx2c. The toxins these genes encode
differ in their in vitro and experimental phenotypes, but the human population-level impact of these
differences is poorly understood. Using Shiga toxin-encoding bacteriophage insertion typing and
real-time polymerase chain reaction, we genotyped isolates from 936 E. coli O157:H7 cases and
verified HUS status via chart review. We compared the HUS risk between isolates with stx2a and
those with stx2a and another gene and estimated additive interaction of the stx genes. Adjusted for
age and symptoms, the HUS incidence of E. coli O157:H7 containing stx2a alone was 4.4% greater
(95% confidence interval (CI) −0.3%, 9.1%) than when it occurred with stx1a. When stx1a and stx2a
occur together, the risk of HUS was 27.1% lower (95% CI −87.8%, −2.3%) than would be expected if
interaction were not present. At the population level, temporal or geographic shifts toward these
genotypes should be monitored, and stx genotype may be an important consideration in clinically
predicting HUS among E. coli O157:H7 cases.
Keywords: Escherichia coli O157:H7; Shiga toxin-producing Escherichia coli; stx genes; hemolytic
uremic syndrome
Key Contribution: Among individuals infected with Escherichia coli O157:H7, the stx2a-only genotype
confers an absolute increase in hemolytic uremic syndrome risk of 4.4% compared to the stx1a2a
genotype. There is a large negative interaction on the additive scale between stx1a and stx2a at the
population level.

1. Introduction
Escherichia coli O157:H7 is a leading cause of hospitalization for foodborne illness and the
predominant cause of post-diarrheal hemolytic uremic syndrome (HUS) [1]. Characterized by
hemolytic anemia, thrombocytopenia, and renal injury, HUS often necessitates renal replacement
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therapy, has a 1–5% case fatality [2–4], and is believed to be the consequence of vascular injury from
circulating Shiga toxins (Stx) produced by this pathogen [5]. Children <5 years old suffer the highest
incidence of reported E. coli O157:H7 infections, HUS, and death.
Pathogen characteristics are important factors in determining progression to HUS in humans
infected with E. coli O157:H7 and other Stx-producing E. coli (STEC). STEC can express two families of
Stx, its cardinal virulence factor, namely Stx1 and Stx2. These toxins are encoded by several allelic
variants, of which stx1a, stx2a, and stx2c are most common among E. coli O157:H7 strains isolated from
humans. The genotype of a single bacterial isolate may contain any or all of these subtypes. While
Stx2, particularly when encoded by stx2a subtype, has been observed more frequently among cases
with severe disease [6–11], previous studies have failed to estimate the risk of HUS attributable to
particular genotypes or stx subtypes. Knowledge of HUS attributable risk by genotype is necessary to
better understand patient prognosis. Moreover, STEC possessing stx2a as the sole Stx-encoding gene
are isolated disproportionately from HUS cases, relative to STEC containing stx1a and stx2a [10–14],
suggesting negative interaction between subtypes. This is a paradox, as one would expect that an
E. coli O157:H7 that produces two Stx (i.e., Stx1 and Stx2a) would be more virulent than an E. coli
O157:H7 producing Stx2a as the sole toxin.
To elucidate the role of E. coli O157:H7 stx genotypes in the development of HUS at the population
level, we estimated (1) the risk of HUS associated with observed stx genotypes, (2) overall and
age-specific changes in risk when stx2a is found alone vs. in combination with other stx alleles,
and (3) the additive interaction between different stx alleles.
2. Results
We stx-genotyped 966 (83%) of the 1160 E. coli O157:H7 isolates from cases reported during the
study period. We could not verify HUS status for 28 hospitalized cases, because they had no chart
available for abstraction. Additionally, two of the isolates we attempted to genotype yielded no stx
genes, leaving 936 cases for analysis of HUS risk (Figure S1; Supplemental Results). In total, HUS
occurred in 69 cases of all ages (7.4%) (Table 1), including 52 of 372 (14.0%) children <10 years old
(Table S1).
Table 1. Characteristics of E. coli O157 cases by Shiga toxin genotype.
stx1a2a (n = 439)
Median (IQR)

18.0 (5.00, 42.5)

Present
Absent
Missing

50 (11.4%)
350 (79.7%)
39 (8.9%)

Yes
No

42 (9.6%)
397 (90.4%)

Present
Absent
Missing

433 (98.6%)
2 (0.5%)
4 (0.9%)

Present
Absent
Missing

398 (90.7%)
31 (7.1%)
10 (2.3%)

Present
Absent
Missing

204 (46.5%)
223 (50.8%)
12 (2.7%)

Present
Absent
Missing

408 (92.9%)
16 (3.6%)
15 (3.4%)

stx2a-only (n = 225)

stx2a2c (n = 190)

Age (years)
11.0 (4.00, 30.0)
12.0 (4.00, 33.0)
Comorbidity
26 (11.6%)
18 (9.5%)
184 (81.8%)
158 (83.2%)
15 (6.7%)
14 (7.4%)
Outbreak-related
32 (14.2%)
14 (7.4%)
193 (85.8%)
176 (92.6%)
Diarrhea
221 (98.2%)
187 (98.4%)
3 (1.3%)
1 (0.5%)
1 (0.4%)
2 (1.1%)
Blood in stool
189 (84.0%)
161 (84.7%)
32 (14.2%)
22 (11.6%)
4 (1.8%)
7 (3.7%)
Vomiting
121 (53.8%)
102 (53.7%)
103 (45.8%)
82 (43.2%)
1 (0.4%)
6 (3.2%)
Abdominal pain
204 (90.7%)
175 (92.1%)
13 (5.8%)
8 (4.2%)
8 (3.6%)
7 (3.7%)

Other (n = 82)

Overall (n = 936)

23.0 (8.00, 46.8)

16.0 (5.00, 39.3)

7 (8.5%)
69 (84.1%)
6 (7.3%)

101 (10.8%)
761 (81.3%)
74 (7.9%)

1 (1.2%)
81 (98.8%)

89 (9.5%)
847 (90.5%)

81 (98.8%)
0 (0%)
1 (1.2%)

922 (98.5%)
6 (0.6%)
8 (0.9%)

61 (74.4%)
20 (24.4%)
1 (1.2%)

809 (86.4%)
105 (11.2%)
22 (2.4%)

28 (34.1%)
52 (63.4%)
2 (2.4%)

455 (48.6%)
460 (49.1%)
21 (2.2%)

71 (86.6%)
8 (9.8%)
3 (3.7%)

858 (91.7%)
45 (4.8%)
33 (3.5%)
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stx1a2a (n = 439)

stx2a-only (n = 225)

stx2a2c (n = 190)

Other (n = 82)

Overall (n = 936)

20 (24.4%)
53 (64.6%)
9 (11.0%)

335 (35.8%)
537 (57.4%)
64 (6.8%)

20 (24.4%)
60 (73.2%)
2 (2.4%)

365 (39.0%)
558 (59.6%)
13 (1.4%)

1 (1.2%)
81 (98.8%)

69 (7.4%)
867 (92.6%)

1 (1.2%)
81 (98.8%)

36 (3.8%)
900 (96.2%)

Fever
Present
Absent
Missing

167 (38.0%)
245 (55.8%)
27 (6.2%)

Yes
No
Missing

167 (38.0%)
263 (59.9%)
9 (2.1%)

Yes
No

28 (6.4%)
411 (93.6%)

Yes
No

11 (2.5%)
428 (97.5%)

78 (34.7%)
70 (36.8%)
132 (58.7%)
107 (56.3%)
15 (6.7%)
13 (6.8%)
Hospitalized
93 (41.3%)
85 (44.7%)
130 (57.8%)
105 (55.3%)
2 (0.9%)
0 (0%)
HUS
24 (10.7%)
16 (8.4%)
201 (89.3%)
174 (91.6%)
RRT
14 (6.2%)
10 (5.3%)
211 (93.8%)
180 (94.7%)

Patient or caregiver reported presence of fever; if temperature was reported, fever was defined as ≥38.0 ◦ C. ‘Other’
genotype includes stx1a-only, stx1a2a2c, stx1a2c, and stx2c-only genotypes. Abbreviations: HUS, hemolytic uremic
syndrome; IQR, interquartile range; RRT, renal replacement therapy.

stx1a2a was the most common genotype (439/936; 46.9%), followed by stx2a-only (225/936; 24.0%)
and stx2a2c (190/936; 20.3%) genotypes (Table 1). Four other genotypes were isolated from the remaining
82 cases (8.8%); these were not included in the primary analysis. We observed a broad age distribution
across all genotypes. The stx2a-only genotype was more commonly isolated from outbreak cases than
other genotypes were. Diarrhea occurred in >98% of cases, regardless of genotype. Blood in the stool
was slightly more common and vomiting was slightly less common among stx1a2a genotype cases,
relative to stx2a-only and stx2a2c genotypes. Cases from which one of the less common genotypes was
isolated experienced generally milder illnesses.
2.1. Risk of HUS
The cumulative incidence of HUS was greatest among stx2a-only-infected cases, with 10.7%
[95% confidence interval (CI) 7.0%, 15.5%] of cases progressing to HUS (Figure 1). Cumulative
incidence was 6.4% (95% CI 4.3%, 9.1%) among those with a stx1a2a strain. After adjusting for age and
symptoms, HUS incidence of the stx2a-only genotype was 4.4% (95% CI −0.3%, 9.1%) greater than the
stx1a2a genotype (Table 2). This means that if the 439 individuals infected with stx1a2a had instead
been infected with an stx2a-only strain, 47 cases of HUS would have been expected to occur, or 19 more
than the 28 cases of HUS observed, age and symptoms being equal. The adjusted relative risk (RR)
was 1.58 (95% CI 0.98, 2.56).
Table 2. Excess risk of HUS due to stx2a vs. other genotypes.
RD (95% CI)
stx2a vs.

stx1a2a
stx2a2c
Other

RR (95% CI)

Crude

Age-Adjusted

Fully
Adjusted

Crude

0.043
(−0.003, 0.089)
0.022
(−0.034, 0.079)
0.095
(0.048, 0.141)

0.036
(−0.010, 0.082)
0.021
(−0.035, 0.077)
0.082
(0.037, 0.127)

0.044
(−0.003, 0.091)
0.03
(−0.026, 0.087)
0.058
(0.013, 0.103)

1.67
(0.99, 2.82)
1.27
(0.69, 2.31)
8.96
(1.23, 65.2)

Age-Adjusted

Fully
Adjusted

1.52
(0.9, 2.54)
1.24
(0.68, 2.25)
7.28
(0.98, 54.14)

1.58
(0.98, 2.56)
1.43
(0.83, 2.45)
4.65
(0.7, 31.08)

Fully adjusted models are adjusted for age, blood in stool, vomiting, and fever. Abbreviations: CI, confidence
interval; HUS, hemolytic uremic syndrome; RD, risk difference; RR, relative risk.
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2.2. Risk of HUS in Children

HUS incidence was 8.4% (95% CI 4.9%, 13.3%) among stx2a2c-infected cases (Figure 1). There
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2.2. Risk of HUS in Children

2.3. Risk of Renal Replacement Therapy
Children <10 years constituted 40% (372/936) of reported E. coli O157:H7 cases but 75% (52/69)

The
cumulative
incidence
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replacement
therapy (RRT)
wasof6.2%
CIfrom
3.4%,
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2.4. stx Allelic Interaction
We detected sub-additive interaction of stx1a and stx2a. After accounting for age and symptoms,
when stx1a and stx2a occur together in E. coli O157:H7 (i.e., as the stx1a2a genotype), the risk of HUS
was 27.1% lower (95% CI −87.8%, −2.3%) than would be expected if interaction were not present, based
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on the risk of HUS associated with the stx1a-only and stx2a-only genotypes (Figure S2, Supplemental
Results). No interaction was observed for stx2a and stx2c (−3.0%; 95% CI −8.5%, 2.4%).
2.5. Sensitivity Analysis
After restricting the analysis to hospitalized cases and adjusting for age, fever, and antibiotic use,
RD and RR point estimates slightly exceeded or were similar to those in the primary analysis (Table S4;
Supplemental Results). For stx2a-only vs. stx1a2a, the RD was 7.2% with a wide confidence interval
(95% CI −2.2%, 16.5%), and the RR was 1.34 (95% CI 0.87, 2.05).
After reassigning the genotype of the isolates that might have lost an stx gene after isolation,
the excess risk associated with the stx2a-only genotype was similar or marginally in excess of that seen
in the primary analysis. The adjusted RD of HUS incidence of stx2a-only vs. stx1a2a was 5.2% (95% CI
0%, 10.4%), and the adjusted RR was 1.7 (95% CI 1.04, 2.79) (Table S5).
3. Discussion
We have demonstrated that the risk of HUS is substantially associated with the E. coli O157:H7
stx genotype. For the major genotypes, cumulative incidence of HUS increased from 6.4% for the
stx1a2a genotype to 10.7% for the stx2a-only genotype. Among children <5 years, the incidence of HUS
increased from 13.8% for the stx2a2c genotype to 16.9% for the stx2a-only genotype. We estimated that
the stx2a-only genotype causes HUS in 4.4% more infected cases (i.e., ~4 more HUS cases per 100 E. coli
O157:H7 cases) than the stx1a2a genotype does, adjusting for age and symptoms. Moreover, we found
a strong negative interaction on the additive scale between stx1a and stx2a. Similarly, the stx2a-only
genotype increased risk of RRT by 3.8%. We did not identify a difference in risk between the stx2a-only
and stx2a2c genotypes.
Since early E. coli O157:H7 outbreaks, epidemiologic studies have found an association between
Stx2 and HUS. However, with few exceptions [6,9,11,15], studies have not offered genotype-specific
incidence or adjusted measures of excess risk. Consequently, the magnitude of how genotypic variations
in virulence impact HUS incidence across populations has been unclear. We identified a substantial
increase in HUS risk associated with the stx2a genotype as compared to the stx1a2a genotype, two of
the most common genotypes in North America and Japan [9,11,16–19]. The virulence of the stx2a2c
genotype, predominant in other settings [7,8,20,21], was similar to that of the stx2a-only genotype.
This increased risk is not trivial. Over our 10-year study period in Washington State, we would have
expected to see 19 additional HUS cases had stx2a strains replaced stx1a2a strains, increasing the HUS
rate by a quarter, all else being equal. On a relative scale, that would amount to a 28% increase in the
number of HUS cases. The public health impact of shifts in the E. coli O157 population is not merely
theoretical. A relative decline in stx1a2a infections and increase in stx2a, with or without stx2c, can be
observed between early studies in Washington State [11] and our current data, and we have shown a
similar secular bacterial population shift on the absolute scale within the 10 years of our study [22].
These differences may explain variation in HUS incidence between geographic regions where the
dominant stx genotypes differ.
Several lines of experimental evidence are harmonious with our epidemiologic findings that
E. coli O157:H7 containing one toxin gene (i.e., stx2) are more virulent than E. coli O157:H7 containing
two toxin genes (i.e., stx1stx2). Donohue-Rolfe et al. increased the neurovirulence of an stx2+/stx1+
E. coli O157:H7 in a gnotobiotic piglet model by deleting the stx1 gene [13], Russo et al. showed that
enterally administered Stx1a reduces enterally-administered Stx2a-mediated toxicity [23], and Petro et
al. reported that Stx1a neutralizes the toxicity of Stx2 [14]. This last paper postulated that the effect is
probably caused by competitive inhibition of the more potent Stx2a by the less potent Stx1a, and we
favor this interpretation. However, they also note that they could not exclude the possibility that the
attenuation of Stx2a toxicity is related to a less specific immunomodulatory effect of Stx1a, which
diminishes host cell response to Stx2a intoxication. The exact mechanism underlying this paradoxical
genotype finding is likely to remain speculative for some time. Nonetheless, our multivariable analysis

Toxins 2019, 11, 607

6 of 11

of bacterial genotype and disease outcome resembles findings from smaller, older studies in which
only univariate associations were tested, lending human relevance to the experimental data.
We have previously reported lack of association between phylogenetic lineages and HUS in
this population, both overall and among children <10 years of age [24]. There is some concordance
between lineage and stx genotype, with the most common human-biased lineages each having a
dominant genotype [24]. However, genotypic variation within lineages does exist. That we observed
an association between stx genotype and HUS where we failed to observe one between phylogenetic
lineage and HUS suggests that lineage is an imperfect surrogate for stx genotype.
When stratifying by age group, we observed a slightly lower point estimate among children
<10 years as among all cases when comparing stx2a-only and stx1a2a genotypes, but the estimate
was imprecise. Although this may indicate there is no association between stx genotype and HUS
in this age group, it is more likely that our sample size was insufficient to detect the difference with
precision. Although phylogenetic lineage analysis previously suggested the stx1a2a genotype conferred
protection to children <5 years [24], we did not observe this reversal in the current study. However,
given the imprecision, we cannot say conclusively that the association holds in children <10 years.
We believe further study is warranted to understand the effect of genotype in specific age groups.
The stx2a-only genotype is also more associated with greater HUS incidence than the less common
‘other’ genotypes included in our study. Notably, only 6 of these 82 isolates possessed a stx2a gene,
and those were combined with stx1a (as well as stx2c in some), so we would expect their virulence
to be attenuated relative to stx2a-only isolates. This is supported by HUS frequencies by genotype
in some other studies [6,8,21], but not all [7]. Previous work has shown that many of these specific
isolates are in cattle-biased phylogenetic lineages [24] that are rarely isolated from humans. Factors
that confer lower infectivity and/or pathogenicity may also be involved in their lower virulence.
Only one case in our study developed HUS among those infected by one of the ‘other’ genotypes.
This case was an otherwise healthy young child with no unusual risk factors. The isolate from this case
was previously typed into the phylogenetic lineage dominated by the stx1a2a genotype. It is possible
that a stx2a allele was lost in the host or on plating, and the Stx-encoding bacteriophage insertion (SBI)
type of this specific isolate, and three others included in this analysis, is consistent with a stx1a2a isolate
that lost its stx2a bacteriophage. Loss of stx genes from cultured isolates is a recognized phenomenon,
with all or only a subset of genes being lost [12,25–28], and in broth culture, a subset of E. coli O157:H7
underwent spontaneous excision of the bacteriophages containing the stx genes [25]. We excluded two
isolates that had no stx genes and explored the possibility that other isolates had lost one or more stx
genes. When using lineage typing and pulsed field gel electrophoresis (PFGE) patterns as a guide to
reassign the genotype of isolates that had potentially lost a gene, the RD between the stx2a-only and
stx1a2a genotypes increased and HUS risk associated with the stx2a-only and stx2a2c genotypes was
similar, supporting our primary findings.
While our study focused on E. coli O157:H7 cases, our findings may be more broadly applicable to
other STEC given that Stx toxicity is driven largely by the B subunit of the toxin [29]. Non-O157 STEC
are increasingly reported because of the widespread adoption of multiplex PCR platforms that detect
stx1 and stx2 sequences. However, caution should be exercised when detecting a stx1a-only E. coli
O157:H7 because of the potential that stx2a was lost or because of sampling error, stx1a-only non-O157
STEC are more common and thus more likely to be genuine results. However, not all multiplex panels
distinguish stx1 and stx2, and some laboratories choose not to release stx type; in these cases, follow-up
enzyme immunoassays for the toxin, PCR, or whole genome sequencing should be considered if
knowledge of the stx genotype would contribute to patient care.
Our data have implications for etiologic studies, aside from outbreak analyses, and intervention
studies designed to prevent E. coli O157:H7 infections from progressing to HUS. Knowledge of genotype
can be used to evaluate effect heterogeneity and could potentially confound apparent associations.
In future small clinical trials, stratified randomization by genotype should be considered, if feasible.
If not, the infecting strain genotype should be taken into account in the analysis of efficacy of the
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intervention. Additionally, stx genotype may be a candidate for clinical decision support tools designed
to predict the development of HUS and need for RRT.
The analysis was restricted to those cases who sought care, provided a specimen, and were
reported. People infected with E. coli O157 who do not seek care presumably have less severe disease.
Factors driving care-seeking and stool testing include the presence of hematochezia, pain, a high
number of diarrheal episodes per day, or concomitant vomiting. If certain genotypes are less likely to
cause these symptoms, their proportions of HUS will be overestimated relative to genotypes more
likely to cause these symptoms. If the stx2a-only genotype is more likely to cause severe symptoms
than the referent genotype (e.g., stx1a2a), the referent genotype is likely underreported to a greater
degree than stx2a. Assuming non-severe E. coli O157:H7 cases who were not reported did not have
HUS, the true RD and RR would be greater than that observed in this case. Conversely, if the referent
genotype causes more severe symptoms than the stx2a-only genotype, the true RD and RR would be
lower than those we observed.
Our analysis was limited by missing genotype and HUS status. The largest factor influencing
isolate missingness was year of isolation. The most probable associated mechanisms, such as genomic
degradation and being misplaced, are likely to be random and not related to genotype or HUS status.
Thus, we believe that our analysis is unbiased by these gaps in data. Moreover, among genotyped
isolates, those missing HUS status were proportionally distributed across genotypes, suggesting there
would be little change in the estimates. The association between fever and missing HUS status likely
reflects that patients are more likely to seek care if they have a fever but does not impact the association
between genotype and HUS.
4. Conclusions
We have estimated the excess risk of HUS and RRT attributable to stx2a-only E. coli O157:H7,
relative to the stx1a2a genotype, demonstrating the population-level implications of the purported
attenuation of stx2a virulence by stx1a. If stx2a-only strains had replaced stx1a2a strains in our
population, we would have observed >25% more HUS cases. Public health officials should be aware of
temporal and geographic variation in dominant stx genotypes, because they may imply an escalation
of the risk of HUS among infected individuals. While the risk of HUS among stx1a2a-infected cases
is less than if they were infected with a stx2a-only isolate, these patients are still at risk of HUS and
should be managed with that possibility in mind. Future work is needed to understand genotypic
HUS risk in different age groups and acuity levels.
5. Materials and Methods
5.1. Study Population
We conducted a population-based retrospective cohort study of all culture-confirmed E. coli
O157:H7 cases reported to the Washington State department of health (DOH) from 2005 through 2014.
Demographic information, potential exposures, and details of the course of illness were obtained from
case report forms. We confirmed HUS status, the primary outcome, and RRT, the secondary outcome,
during a review of hospitalized E. coli O157:H7 cases from the study sample. Data collection has
been detailed previously [24]. HUS was defined as hematocrit <30%, platelet count <150,000/mm3 ,
and serum creatinine concentration above the normal for age [30], with all criteria met on the same day.
We assumed all non-hospitalized cases did not have HUS because of the severity of this disease outcome.
The Washington State institutional review board designated this study as exempt. The University
of Calgary conjoint health research ethics board approved this study.
5.2. Genotyping
stx genotype was the exposure of interest, classified as combinations of stx1a, stx2a, and stx2c.
The three most common genotypes are stx1a-/stx2a+/stx2c-, stx1a+/stx2a+/stx2c-, and stx1a-/stx2a+/stx2c+.
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We refer to them as stx2a-only, stx1a2a, and stx2a2c, respectively, for the purpose of this paper. Isolates
were genotyped in two batches.
SBI typing, a multiplex PCR method, was used to characterize the genotypes of 690 isolates
at Washington State University. The SBI typing detects 12 targets identifying the insertion of three
Stx-encoding bacteriophages and three specific stx subtypes (stx1a, stx2a, and stx2c) and has been
described previously [31,32].
An additional 276 isolates were genotyped at the University of Alberta using a real-time PCR assay,
described previously [33,34]. Isolates were grown on sheep blood agar plates (Dalynn Biologicals,
Calgary, AB, Canada) for 24 h. For DNA extraction, a colony from each plate was mixed with rapid
lysis buffer (100 mmol/L NaCl, 10 mmol/L Tris-HCl. pH 8.3, 1 mmol/L EDTA, pH 9.0; 1% Triton X-100)
and then heated to 95 ◦ C for 15 min, followed by centrifugation at 13,000g for 15 min. Real-time PCR
was performed on the supernatant as DNA template using either a hydrolysis probe or SYBR green
based approach. For the probe based assays the total reaction volume (20 µL) consisted of: 10 µL
PrimeTime®Gene Expression Master Mix (Integrated DNA Technologies, Coralville, IA, USA), 0.9 µM
of each primer, 0.25 µM of each probe, 5 µL of DNA template, and nuclease-free water (Invitrogen,
Carlsbad, CA, USA). As for the SYBR green based assays, the total reaction volume (20 µL) consisted of:
10 µL Fast SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA), 0.3 µM of each primer,
5 µL of DNA template, and nuclease-free water. All reactions were performed using primers and
probes ordered from Integrated DNA Technologies (Coralville, IA, USA), and were run on Applied
Biosystems®7500 fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA).
5.3. Statistical Analysis
Cases were excluded from analysis if the associated E. coli O157:H7 isolate was not genotyped,
no stx genes were identified during typing, or if the case was hospitalized but HUS status could not
be verified. We summarized demographic and illness characteristics with descriptive statistics and
investigated potential reasons for missing specimens.
We calculated the cumulative incidence and exact binomial 95% CI of HUS by stx genotype as
the number of cases infected with E. coli O157:H7 of a given genotype who developed HUS over the
total number of cases infected with E. coli O157:H7 of that genotype. We assumed the incidence of
HUS among E. coli O157:H7-infected patients unexposed to stx1a, stx2a, and stx2c was the incidence of
atypical HUS, an entirely unrelated disorder, in the general population, 2 × 10−6 [35], or essentially 0.
As such, we interpreted cumulative incidence estimates as attributable risks.
To estimate the excess risk of HUS associated with stx2a-only E. coli O157:H7 isolates, we calculated
the RD and RR of that genotype vs. stx1a2a, stx2a2c, and all other genotypes combined. We adjusted
RD and RR estimates for age, to control for confounding, and symptoms most likely to influence
clinical management, specifically blood in the stool, vomiting, and fever, to block an indirect causal
pathway between stx genotype and HUS (Figure 2; Supplemental Methods). We used linear regression
with robust standard errors to estimate RDs and modified Poisson regression with robust standard
errors to estimate RRs. We also calculated the RD for our secondary outcome RRT, fully adjusted
for age and symptoms. In secondary analysis, we estimated the RD and RR for HUS, restricting the
sample to children <10 years old.
We calculated the degree of additive interaction between stx1a and stx2a, and stx2a and stx2c,
separately, using the equation p11 − p10 − p01 + p00 , where the subscripts indicate the presence or absence
of a specific gene. Values >0 and <0 can be interpreted as super-additive and sub-additive interaction,
respectively. Three-way interaction was not considered because of the rarity of stx1a+/stx2a+/stx2c+
isolates. We adjusted for age and symptoms using stabilized inverse probability weights. We used
a bootstrap with 10,000 replicates to calculate 95% bias-corrected and accelerated CIs for interaction
estimates. Multiplicative interaction was not directly assessed (Supplemental Methods).
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Figure 2. Directed acyclic graph of hypothesized relationships among stx genotype (exposure, green oval
Figure 2. Directed acyclic graph of hypothesized relationships among stx genotype (exposure, green
with triangle), HUS (outcome, blue oval with bar), and covariates. Age confounds the genotype-HUS
oval with triangle), HUS (outcome, blue oval with bar), and covariates. Age confounds the genotyperelationship.
is a potential
pathway
from genotype
to HUS
through
symptoms
HUSThere
relationship.
There is indirect
a potential
indirect pathway
from genotype
to HUS
through
symptoms(e.g., blood
in stool, vomiting,
and
clinicalfever)
management
antibiotic
intravenous
fluid administration).
(e.g., bloodfever)
in stool,
vomiting,
and clinical (e.g.,
management
(e.g.,use,
antibiotic
use, intravenous
fluid
administration).
Abbreviation:
HUS,syndrome.
hemolytic uremic syndrome.
Abbreviation:
HUS, hemolytic
uremic
Analysis
SensitivitySensitivity
Analysis
To more fully account for the indirect causal pathway between stx genotype and HUS involving

To more
fully account
formanagement,
the indirect
pathway
between
stxofgenotype
and
HUS involving
symptoms
and clinical
wecausal
conducted
a sensitivity
analysis
RD and RR
estimates
symptomsincluding
and clinical
management,
a sensitivity
analysis
of RD
and RR estimates
adjustment
for antibioticwe
use.conducted
Antibiotic use
was only validated
among
hospitalized
thus limiting
this analysis
that sub-population.
including patients,
adjustment
for antibiotic
use.toAntibiotic
use was only validated among hospitalized patients,
Acknowledging the possibility that E. coli O157:H7 may lose their stx bacteriophages after they
thus limiting this
analysis to that sub-population.
are plated on agar, we conducted a sensitivity analysis reclassifying isolates with atypical stx
Acknowledging
the PFGE
possibility
E. coliusing
O157:H7
may lose
their
stx [24]
bacteriophages
genotype for their
pattern,that
confirmed
phylogenetic
lineage
typing
(Supplemental after they
are platedMethods).
on agar, we conducted a sensitivity analysis reclassifying isolates with atypical stx genotype
for their PFGE
pattern,Materials:
confirmed
phylogenetic
lineage
typing [24] (Supplemental
Methods).
Supplementary
The using
following
are available online
at www.mdpi.com/xxx/s1,
Supplemental
Methods, Supplemental Results, Figure S1: Flow diagram of E. coli O157:H7 cases and associated isolates
included
in analysis,The
Figure
S2: Histogram
of 10,000 bootstrap
Table S1: HUS status by age and stx
Supplementary
Materials:
following
are available
online samples,
at http://www.mdpi.com/2072-6651/11/10/607/s1,
genotype,
Table S2:
Risk of HUS among
E. coli Figure
O157 cases
genotype,
Table S3:
of HUS due
to stx2a
Supplemental
Methods,
Supplemental
Results,
S1:byFlow
diagram
of Excess
E. colirisk
O157:H7
cases
and associated
vs. otherin
genotypes,
children
<10 years old,
S4: bootstrap
Excess risk of
HUS due Table
to stx2aS1:
without
stx by age and
isolates included
analysis,among
Figure
S2: Histogram
ofTable
10,000
samples,
HUSother
status
genes
among
patients,
TableE.S5:
Excess
of HUS
due to stx2a Table
withoutS3:
other
stx genes
stx genotype,
Table
S2:hospitalized
Risk of HUS
among
coli
O157risk
cases
by genotype,
Excess
riskafter
of HUS due to
correcting
for potential
genechildren
loss.
stx2a vs. other
genotypes,
among
<10 years old, Table S4: Excess risk of HUS due to stx2a without other
stx genes among
hospitalizedConceptualization,
patients, Table G.A.M.T.
S5: Excess
HUS dueG.A.M.T.,
to stx2a T.S.,
without
other
stx genes after
Author Contributions:
and risk
L.C.; of
methodology,
S.S., P.I.T.,
S.B.F.,
correcting for
potential
loss.software, formal analysis, and data curation, G.A.M.T.; investigation, T.S. and S.S.;
H.N.O.,
P.M.R.,gene
and L.C.;
resources, H.N.O. and L.C.; writing—original draft preparation, G.A.M.T.; writing—review and editing,
Author Contributions:
Conceptualization, G.A.M.T. and L.C.; methodology, G.A.M.T., T.S., S.S., P.I.T., S.B.F.,
G.A.M.T., T.S., S.S., P.I.T., S.B.F., H.N.O., P.M.R., and L.C.; supervision, P.I.T., S.B.F., P.M.R., and L.C.; funding
H.N.O., P.M.R., and L.C.; software, formal analysis, and data curation, G.A.M.T.; investigation, T.S. and S.S.;
acquisition, G.A.M.T, S.B.F., and L.C.
resources, H.N.O. and L.C.; writing—original draft preparation, G.A.M.T.; writing—review and editing, G.A.M.T.,
T.S., S.S., P.I.T., S.B.F., H.N.O., P.M.R., and L.C.; supervision, P.I.T., S.B.F., P.M.R., and L.C.; funding acquisition,
G.A.M.T., S.B.F., and L.C.

Funding: This study was funded by the Alberta Children’s Hospital Research Institute and the Cumming School
of Medicine/Alberta Health Services Clinical Research Fund. G.A.M.T. was supported by a Canadian Institutes of
Health Research Banting Postdoctoral Fellowship, Alberta Innovates Health Programs Postgraduate Fellowship,
and University of Calgary Eyes High Postdoctoral Fellowship. T.S. was supported by a 2019 Alberta Innovates
Summer Research Studentship. P.I.T. was supported by the Washington University Digestive Disease Research
Core Center (ARAC Core) P30DK052574. S.B.F. was supported by the Alberta Children’s Hospital Foundation
Professorship in Child Health and Wellness.
Acknowledgments: We would like to acknowledge Thomas E. Besser of Washington State University, who
oversaw the banking of isolates and the SBI typing used in this study, as well as the Washington State Department
of Health for the bacterial isolates and data they contributed to this analysis.
Conflicts of Interest: P.I.T. is an unpaid consultant to Inmunova, which is attempting to develop immunotherapy
for the prevention of HUS in people infected with Shiga toxin-producing E. coli; a consultant to Takeda
Pharmaceuticals on childhood digestive disorders and the Bill and Melinda Gates Foundation on neonatal
infections; and a consultant to, member of the scientific advisory board of, and holder of equity in, MediBeacon
Inc for work that is unrelated to this study. S.B.F. is a consultant to Takeda Pharmaceuticals regarding vaccine
development and has received in-kind support for previous studies from Luminex Corporation and BioMerieux
Inc. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the
writing of the manuscript, or in the decision to publish the results.

Toxins 2019, 11, 607

10 of 11

References
1.

2.

3.

4.

5.
6.

7.
8.

9.

10.

11.

12.
13.

14.

15.

16.

17.

Banatvala, N.; Griffin, P.M.; Greene, K.D.; Barrett, T.J.; Bibb, W.F.; Green, J.H.; Wells, J.G. The United
States National Prospective Hemolytic Uremic Syndrome Study: Microbiologic, serologic, clinical,
and epidemiologic findings. J. Infect. Dis. 2001, 183, 1063–1070. [CrossRef] [PubMed]
Gould, L.H.; Demma, L.; Jones, T.F.; Hurd, S.; Vugia, D.J.; Smith, K.; Shiferaw, B.; Segler, S.; Palmer, A.;
Zansky, S.; et al. Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection,
foodborne diseases active surveillance network sites, 2000–2006. Clin. Infect. Dis. 2009, 49, 1480–1485.
[CrossRef] [PubMed]
Mody, R.K.; Gu, W.; Griffin, P.M.; Jones, T.F.; Rounds, J.; Shiferaw, B.; Tobin-D’Angelo, M.; Smith, G.; Spina, N.;
Hurd, S.; et al. Postdiarrheal hemolytic uremic syndrome in United States children: Clinical spectrum and
predictors of in-hospital death. J. Pediatr. 2015, 166, 1022–1029. [CrossRef] [PubMed]
McKee, R.S.; Schnadower, D.; Tarr, P.I.; Xie, J.; Finkelstein, Y.; Desai, N.; Lane, R.D.; Bergmann, K.R.;
Kaplan, R.L.; Hariharan, S.; et al. Predicting Hemolytic Uremic Syndrome and Renal Failure in Shiga
Toxin-Producing Escherichia coli Infected Children. Clin. Infect. Dis. 2019. [CrossRef] [PubMed]
Tarr, P.I.; Gordon, C.A.; Chandler, W.L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic
syndrome. Lancet 2005, 365, 1073–1086. [CrossRef]
Persson, S.; Olsen, K.E.; Ethelberg, S.; Scheutz, F. Subtyping method for Escherichia coli shiga toxin
(verocytotoxin) 2 variants and correlations to clinical manifestations. J. Clin. Microbiol. 2007, 45, 2020–2024.
[CrossRef]
Eklund, M.; Leino, K.; Siitonen, A. Clinical Escherichia coli strains carrying stx genes: Stx variants and
stx-positive virulence profiles. J. Clin Microbiol. 2002, 40, 4585–4593. [CrossRef] [PubMed]
Friedrich, A.W.; Bielaszewska, M.; Zhang, W.L.; Pulz, M.; Kuczius, T.; Ammon, A.; Karch, H. Escherichia coli
harboring Shiga toxin 2 gene variants: Frequency and association with clinical symptoms. J. Infect. Dis. 2002,
185, 74–84. [CrossRef]
Luna-Gierke, R.E.; Griffin, P.M.; Gould, L.H.; Herman, K.; Bopp, C.A.; Strockbine, N.; Mody, R.K. Outbreaks
of non-O157 Shiga toxin-producing Escherichia coli infection: USA. Epidemiol. Infect. 2014, 142, 2270–2280.
[CrossRef]
Orth, D.; Grif, K.; Khan, A.B.; Naim, A.; Dierich, M.P.; Wurzner, R. The Shiga toxin genotype rather than
the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the
hemolytic uremic syndrome. Diagn. Microbiol. Infect. Dis. 2007, 59, 235–242. [CrossRef]
Ostroff, S.M.; Tarr, P.I.; Neill, M.A.; Lewis, J.H.; Hargrett-Bean, N.; Kobayashi, J.M. Toxin genotypes and
plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J. Infect. Dis.
1989, 160, 994–998. [CrossRef] [PubMed]
Cornick, N.A.; Jelacic, S.; Ciol, M.A.; Tarr, P.I. Escherichia coli O157:H7 infections: Discordance between
filterable fecal shiga toxin and disease outcome. J. Infect. Dis. 2002, 186, 57–63. [CrossRef] [PubMed]
Donohue-Rolfe, A.; Kondova, I.; Oswald, S.; Hutto, D.; Tzipori, S. Escherichia coli O157:H7 strains that express
Shiga toxin (Stx) 2 alone are more neurotropic for gnotobiotic piglets than are isotypes producing only Stx1
or both Stx1 and Stx2. J. Infect. Dis. 2000, 181, 1825–1829. [CrossRef] [PubMed]
Petro, C.D.; Trojnar, E.; Sinclair, J.; Liu, Z.M.; Smith, M.; O’Brien, A.D.; Melton-Celsa, A. Shiga Toxin Type 1a
(Stx1a) Reduces the Toxicity of the More Potent Stx2a In Vivo and In Vitro. Infect. Immun. 2019, 87. [CrossRef]
[PubMed]
Jelacic, S.; Wobbe, C.L.; Boster, D.R.; Ciol, M.A.; Watkins, S.L.; Tarr, P.I.; Stapleton, A.E. ABO and P1 blood
group antigen expression and stx genotype and outcome of childhood Escherichia coli O157:H7 infections.
J. Infect. Dis. 2002, 185, 214–219. [CrossRef]
Gouveia, S.; Proctor, M.E.; Lee, M.S.; Luchansky, J.B.; Kaspar, C.W. Genomic comparisons and Shiga toxin
production among Escherichia coli O157:H7 isolates from a day care center outbreak and sporadic cases in
southeastern Wisconsin. J. Clin. Microbiol. 1998, 36, 727–733.
Iyoda, S.; Manning, S.D.; Seto, K.; Kimata, K.; Isobe, J.; Etoh, Y.; Ichihara, S.; Migita, Y.; Ogata, K.; Honda, M.;
et al. Phylogenetic Clades 6 and 8 of Enterohemorrhagic Escherichia coli O157:H7 With Particular stx Subtypes
are More Frequently Found in Isolates From Hemolytic Uremic Syndrome Patients Than From Asymptomatic
Carriers. Open Forum Infect. Dis. 2014, 1, ofu061. [CrossRef]

Toxins 2019, 11, 607

18.

19.

20.
21.

22.

23.
24.

25.
26.
27.

28.

29.

30.
31.

32.
33.

34.
35.

11 of 11

Kawano, K.; Okada, M.; Haga, T.; Maeda, K.; Goto, Y. Relationship between pathogenicity for humans and
stx genotype in Shiga toxin-producing Escherichia coli serotype O157. Eur. J. Clin. Microbiol. Infect. Dis. 2008,
27, 227–232. [CrossRef]
Tostes, R.; Goji, N.; Amoako, K.; Chui, L.; Kastelic, J.; DeVinney, R.; Stanford, K.; Reuter, T. Subtyping
Escherichia coli Virulence Genes Isolated from Feces of Beef Cattle and Clinical Cases in Alberta. Foodborne
Pathog. Dis. 2017, 14, 35–42. [CrossRef]
Ashton, P.M.; Perry, N.; Ellis, R.; Petrovska, L.; Wain, J.; Grant, K.A.; Jenkins, C.; Dallman, T.J. Insight into Shiga
toxin genes encoded by Escherichia coli O157 from whole genome sequencing. PeerJ 2015, 3, e739. [CrossRef]
Leotta, G.A.; Miliwebsky, E.S.; Chinen, I.; Espinosa, E.M.; Azzopardi, K.; Tennant, S.M.; Robins-Browne, R.M.;
Rivas, M. Characterisation of Shiga toxin-producing Escherichia coli O157 strains isolated from humans in
Argentina, Australia and New Zealand. BMC Microbiol. 2008, 8, 46. [CrossRef] [PubMed]
Tarr, G.A.; Shringi, S.; Phipps, A.I.; Besser, T.E.; Mayer, J.; Oltean, H.N.; Wakefield, J.; Tarr, P.I.; Rabinowitz, P.
Geogenomic Segregation and Temporal Trends of Human Pathogenic Escherichia coli O157:H7, Washington,
USA, 2005–2014(1). Emerg. Infect. Dis. 2018, 24, 32–39. [CrossRef] [PubMed]
Russo, L.M.; Melton-Celsa, A.R.; O’Brien, A.D. Shiga Toxin (Stx) Type 1a Reduces the Oral Toxicity of Stx
Type 2a. J. Infect. Dis. 2016, 213, 1271–1279. [CrossRef] [PubMed]
Tarr, G.A.; Shringi, S.; Oltean, H.N.; Mayer, J.; Rabinowitz, P.; Wakefield, J.; Tarr, P.I.; Besser, T.E.; Phipps, A.I.
Importance of case age in the purported association between phylogenetics and hemolytic uremic syndrome
in Escherichia coli O157:H7 infections. Epidemiol. Infect. 2018. [CrossRef] [PubMed]
Shaikh, N.; Tarr, P.I. Escherichia coli O157:H7 Shiga toxin-encoding bacteriophages: Integrations, excisions,
truncations, and evolutionary implications. J. Bacteriol. 2003, 185, 3596–3605. [CrossRef] [PubMed]
Leopold, S.R.; Shaikh, N.; Tarr, P.I. Further evidence of constrained radiation in the evolution of pathogenic
Escherichia coli O157:H7. Infect. Genet. Evol. 2010, 10, 1282–1285. [CrossRef]
Trine, M.L.; Jørgensen, H.J.; O’Sullivan, K.; Bohlin, J.; Ligård, G.; Granum, P.E.; Lindbäck, T. The highly
virulent 2006 Norwegian EHEC O103:H25 outbreak strain is related to the 2011 German O104:H4 outbreak
strain. PLoS ONE 2012, 7, e31413. [CrossRef]
Bielaszewska, M.; Prager, R.; Köck, R.; Mellmann, A.; Zhang, W.; Tschäpe, H.; Tarr, P.I.; Karch, H. Shiga
toxin gene loss and transfer in vitro and in vivo during enterohemorrhagic Escherichia coli O26 infection in
humans. Appl. Environ. Microbiol. 2007, 73, 3144–3150. [CrossRef]
Russo, L.M.; Melton-Celsa, A.R.; Smith, M.J.; O’Brien, A.D. Comparisons of native Shiga toxins (Stxs) type
1 and 2 with chimeric toxins indicate that the source of the binding subunit dictates degree of toxicity.
PLoS ONE 2014, 9, e93463. [CrossRef]
Meites, S.; Buffone, G.J. Pediatric Clinical Chemistry: Reference (Normal) Values; AACC Press: Washington, DC,
USA, 1989.
Jung, W.K.; Bono, J.L.; Clawson, M.L.; Leopold, S.R.; Shringi, S.; Besser, T.E. Lineage and genogroup-defining
single nucleotide polymorphisms of Escherichia coli O157:H7. Appl. Environ. Microbiol. 2013, 79, 7036–7041.
[CrossRef]
Shringi, S.; Schmidt, C.; Katherine, K.; Brayton, K.A.; Hancock, D.D.; Besser, T.E. Carriage of stx2a differentiates
clinical and bovine-biased strains of Escherichia coli O157. PLoS ONE 2012, 7, e51572. [CrossRef] [PubMed]
Chui, L.; Couturier, M.R.; Chiu, T.; Wang, G.; Olson, A.B.; McDonald, R.R.; Antonishyn, N.A.; Horsman, G.;
Gilmour, M.W. Comparison of Shiga toxin-producing Escherichia coli detection methods using clinical stool
samples. J. Mol. Diagn. 2010, 12, 469–475. [CrossRef] [PubMed]
Zhi, S.; Szelewicki, J.; Ziebell, K.; Parsons, B.; Chui, L. General detection of Shiga toxin 2 and subtyping of
Shiga toxin 1 and 2 in Escherichia coli using qPCR. J. Microbiol. Methods 2019, 159, 51–55. [CrossRef] [PubMed]
Noris, M.; Remuzzi, G. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009, 361, 1676–1687.
[CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).

